

Peter Kojo Quashie

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9151210/peter-kojo-quashie-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

35
papers

844
citations

14
h-index

29
g-index

39
ext. papers

1,032
ext. citations

7.3
avg, IF

3.69
L-index

#	Paper	IF	Citations
35	Genetic diversity of SARS-CoV-2 infections in Ghana from 2020-2021.. <i>Nature Communications</i> , 2022 , 13, 2494	17.4	2
34	A year of genomic surveillance reveals how the SARS-CoV-2 pandemic unfolded in Africa. <i>Science</i> , 2021 , 374, 423-431	33.3	35
33	Rapid, Cheap, and Effective COVID-19 Diagnostics for Africa. <i>Diagnostics</i> , 2021 , 11,	3.8	1
32	Progressive emergence of an S153F plus R263K combination of integrase mutations in the proviral DNA of one individual successfully treated with dolutegravir. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 639-647	5.1	0
31	Genomic analysis of SARS-CoV-2 reveals local viral evolution in Ghana. <i>Experimental Biology and Medicine</i> , 2021 , 246, 960-970	3.7	9
30	Identification of a Pyridoxine-Derived Small-Molecule Inhibitor Targeting Dengue Virus RNA-Dependent RNA Polymerase. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 600-8	5.9	29
29	Dolutegravir maintains a durable effect against HIV replication in tissue culture even after drug washout. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 2810-5	5.1	7
28	Subtype-specific analysis of the K65R substitution in HIV-1 that confers hypersusceptibility to a novel nucleotide-competing reverse transcriptase inhibitor. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 3189-96	5.9	4
27	Characterization of the Drug Resistance Profiles of Integrase Strand Transfer Inhibitors in Simian Immunodeficiency Virus SIVmac239. <i>Journal of Virology</i> , 2015 , 89, 12002-13	6.6	6
26	Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 405-11	5.1	28
25	A resveratrol analog termed 3,3a4,4a5,5ahexahydroxy-trans-stilbene is a potent HIV-1 inhibitor. <i>Journal of Medical Virology</i> , 2015 , 87, 2054-60	19.7	11
24	The R263K substitution in HIV-1 subtype C is more deleterious for integrase enzymatic function and viral replication than in subtype B. <i>Aids</i> , 2015 , 29, 1459-66	3.5	12
23	Structural Studies of the HIV-1 Integrase Protein: Compound Screening and Characterization of a DNA-Binding Inhibitor. <i>PLoS ONE</i> , 2015 , 10, e0128310	3.7	14
22	Differential effects of the G118R, H51Y, and E138K resistance substitutions in different subtypes of HIV integrase. <i>Journal of Virology</i> , 2015 , 89, 3163-75	6.6	51
21	The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness. <i>Retrovirology</i> , 2014 , 11, 7	3.6	60
20	Integrase strand transfer inhibitors in the management of HIV-positive individuals. <i>Annals of Medicine</i> , 2014 , 46, 123-9	1.5	38
19	The R263K mutation in HIV integrase that is selected by dolutegravir may actually prevent clinically relevant resistance to this compound. <i>Journal of the International AIDS Society</i> , 2014 , 17, 19518	5.4	10

18	HIV-1 group O integrase displays lower susceptibility to raltegravir and has a different mutational pathway for resistance than HIV-1 group M. <i>Journal of the International AIDS Society</i> , 2014 , 17, 19738	5.4	3
17	Biochemical Analysis of the Role of G118R-Linked Dolutegravir Drug Resistance Substitutions in HIV-1 Integrase. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 3580-3580	5.9	2
16	Effect of HIV-1 integrase resistance mutations when introduced into SIVmac239 on susceptibility to integrase strand transfer inhibitors. <i>Journal of Virology</i> , 2014 , 88, 9683-92	6.6	21
15	HIV-1 group O integrase displays lower enzymatic efficiency and higher susceptibility to raltegravir than HIV-1 group M subtype B integrase. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 7141-50	5.9	6
14	Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 2733-40	5.1	41
13	Biochemical Analysis of the Role of G118R-Linked Dolutegravir Drug Resistance Substitutions in HIV-1 Integrase. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 633-633	5.9	2
12	Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure. <i>Retrovirology</i> , 2013 , 10, 22	3.6	103
11	HIV Drug Resistance and the Advent of Integrase Inhibitors. <i>Current Infectious Disease Reports</i> , 2013 , 15, 85-100	3.9	26
10	Development of a fluorescence-based HIV-1 integrase DNA binding assay for identification of novel HIV-1 integrase inhibitors. <i>Antiviral Research</i> , 2013 , 98, 441-8	10.8	15
9	Evolution of HIV integrase resistance mutations. <i>Current Opinion in Infectious Diseases</i> , 2013 , 26, 43-9	5.4	50
8	Biochemical analysis of the role of G118R-linked dolutegravir drug resistance substitutions in HIV-1 integrase. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 6223-35	5.9	56
7	Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir. <i>Journal of Virology</i> , 2012 , 86, 2696-705	6.6	188
6	Explaining the unexpected COVID-19 trends and potential impact across Africa.. <i>F1000Research</i> , 10, 11773.6		
5	Low COVID-19 impact in Africa: The multifactorial Nexus. <i>AAS Open Research</i> , 4, 47	1.8	1
4	Trends of SARS-CoV-2 antibody prevalence in selected regions across Ghana		1
3	A year of genomic surveillance reveals how the SARS-CoV-2 pandemic unfolded in Africa		3
2	Empowering Early Career Researchers to Improve Science		2
1	Trends of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody prevalence in selected regions across Ghana. <i>Wellcome Open Research</i> , 6, 173	4.8	3

